Free Trial

Laboratory Co. of America (LH) Stock Forecast & Price Target

Laboratory Co. of America logo
$246.34 -0.15 (-0.06%)
Closing price 02/18/2025 03:59 PM Eastern
Extended Trading
$246.29 -0.05 (-0.02%)
As of 02/18/2025 06:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Laboratory Co. of America - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
3
Buy
13

Based on 16 Wall Street analysts who have issued ratings for Laboratory Co. of America in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 16 analysts, 3 have given a hold rating, 12 have given a buy rating, and 1 has given a strong buy rating for LH.

Consensus Price Target

$265.31
7.70% Upside
According to the 16 analysts' twelve-month price targets for Laboratory Co. of America, the average price target is $265.31. The highest price target for LH is $290.00, while the lowest price target for LH is $230.00. The average price target represents a forecasted upside of 7.70% from the current price of $246.34.
Get the Latest News and Ratings for LH and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Laboratory Co. of America and its competitors.

Sign Up

LH Analyst Ratings Over Time

TypeCurrent Forecast
2/20/24 to 2/19/25
1 Month Ago
1/21/24 to 1/20/25
3 Months Ago
11/22/23 to 11/21/24
1 Year Ago
2/20/23 to 2/20/24
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
12 Buy rating(s)
12 Buy rating(s)
10 Buy rating(s)
8 Buy rating(s)
Hold
3 Hold rating(s)
3 Hold rating(s)
4 Hold rating(s)
3 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$265.31$260.54$255.92$241.86
Forecasted Upside7.70% Upside9.27% Upside6.45% Upside12.15% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy

LH Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

LH Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Laboratory Co. of America Stock vs. The Competition

TypeLaboratory Co. of AmericaMedical CompaniesS&P 500
Consensus Rating Score
2.88
2.82
2.53
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside7.70% Upside27,861.93% Upside12.84% Upside
News Sentiment Rating
Positive News

See Recent LH News
Neutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
2/10/2025Piper Sandler
2 of 5 stars
D. Westenberg
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetNeutral ➝ Neutral$240.00 ➝ $260.00+5.79%
2/7/2025Barclays
3 of 5 stars
L. Sergott
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetEqual Weight ➝ Equal Weight$271.00 ➝ $260.00+5.61%
2/6/2025Jefferies Financial Group
2 of 5 stars
Tycho Peterson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$275.00 ➝ $290.00+17.25%
1/28/2025UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Kevin Caliendo
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetBuy ➝ Buy$293.00 ➝ $286.00+14.61%
1/7/2025Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
E. Anderson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeIn-Line ➝ Outperform$260.00 ➝ $265.00+15.42%
12/17/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$260.00 ➝ $270.00+17.38%
12/13/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$262.00 ➝ $271.00+16.67%
10/30/2024Hsbc Global Res
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Herholdt
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
10/30/2024HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy
10/25/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$282.00 ➝ $289.00+25.61%
8/2/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetHold ➝ Hold$220.00 ➝ $230.00-2.35%
8/2/2024Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$255.00 ➝ $275.00+18.79%
5/30/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$261.00 ➝ $243.00+25.49%
3/25/2024Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy$250.00+17.23%
2/26/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Cherny
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
2/26/2024Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$260.00+18.63%
10/31/2023Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$257.00 ➝ $230.00+16.07%
8/14/2023Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$290.00 ➝ $270.00+23.85%
8/2/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$247.41 ➝ $231.00+8.14%
4/26/2023Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$260.00 ➝ $235.00+6.14%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 06:01 AM ET.


Should I Buy Laboratory Co. of America Stock? LH Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Saturday, February 8, 2025. Please send any questions or comments about these Laboratory Co. of America pros and cons to contact@marketbeat.com.

Laboratory Co. of America
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Laboratory Co. of America Holdings:

  • The stock has a current price of $247.94, which is near its 52-week high of $258.59, indicating strong market performance and investor confidence.
  • Recent analyst upgrades, including a price target increase from Piper Sandler to $240.00 and from Bank of America to $271.00, suggest positive sentiment and potential for further price appreciation.
  • The company reported a quarterly earnings per share (EPS) of $3.45, exceeding the consensus estimate of $3.40, which reflects strong operational performance and profitability.
  • Laboratory Co. of America Holdings has a moderate buy consensus rating from analysts, with twelve buy ratings and only one strong buy, indicating a generally favorable outlook among market experts.
  • The company has a dividend yield of 1.17% with a quarterly dividend of $0.72 per share, providing investors with a steady income stream in addition to potential capital gains.

Laboratory Co. of America
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Laboratory Co. of America Holdings for these reasons:

  • Insider selling activity has been notable, with executives selling a total of 24,572 shares worth $5,915,209 in the last three months, which may signal a lack of confidence in the stock's future performance.
  • The stock has experienced a slight decline of 0.7% recently, which could indicate short-term volatility and market uncertainty.
  • The company's debt-to-equity ratio is 0.67, which, while manageable, suggests that the company is using a significant amount of debt to finance its operations, potentially increasing financial risk.
  • Despite positive earnings, the net margin of 5.73% indicates that the company may face challenges in maintaining profitability amidst competitive pressures in the medical research sector.
  • With a current ratio of 1.44, while above 1, it suggests that the company has just enough short-term assets to cover its short-term liabilities, which may raise concerns about liquidity in times of financial stress.

LH Forecast - Frequently Asked Questions

According to the research reports of 16 Wall Street equities research analysts, the average twelve-month stock price forecast for Laboratory Co. of America is $265.31, with a high forecast of $290.00 and a low forecast of $230.00.

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Laboratory Co. of America in the last year. There are currently 3 hold ratings, 12 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" LH shares.

According to analysts, Laboratory Co. of America's stock has a predicted upside of 7.70% based on their 12-month stock forecasts.

Over the previous 90 days, Laboratory Co. of America's stock had 1 upgrade by analysts.

Laboratory Co. of America has been rated by research analysts at Bank of America, Barclays, Evercore ISI, Jefferies Financial Group, Morgan Stanley, Piper Sandler, and UBS Group in the past 90 days.

Analysts like Laboratory Co. of America more than other "medical" companies. The consensus rating score for Laboratory Co. of America is 2.88 while the average consensus rating score for "medical" companies is 2.82. Learn more on how LH compares to other companies.


This page (NYSE:LH) was last updated on 2/19/2025 by MarketBeat.com Staff
From Our Partners